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1. Introduction 
L-Tyrosine:2_oxoglutarate aminotransferase (EC 
2.6.1 S, TAT) activity can be induced by adenosine 
315kyclic AMP analogs [l-4] and corticosteroids 
[2,5,6] in rat liver and several hepatoma cell lines. The 
mechanism of the induction of TAT by DBcAMP has 
been extensively investigated [l-4]. Actinomycin D 
does not inhibit the induction of TAT activity by 
DBcAMP which indicates a target for DBcAMP at a 
post-transcriptional evel [ 1,4]. We concluded that 
DBcAMP induces the TAT synthesis by an increase 
in the rate of initiation on the TAT mRNA [7]. How- 
ever, under other experimental conditions evidence 
has been obtained that the elongation rate of the ribo- 
somes along the TAT mRNA increased after DBcAMP 
induction [8]. Also, translational experimentsin several 
cell free systems with mRNA isolated from DBcAMP- 
treated rat liver indicate an increase in the amount of 
functional TAT mRNA [9,10]. It seems that depen- 
dent on the experimental conditions DBcAMP exerts 
a pleiotropic effect on TAT synthesis at different levels 
during protein synthesis. Here, we report a hitherto 
undescribed effect of DBcAMP on TAT synthesis in 
Reuber H35 hepatoma cells. The induction of TAT 
synthesis by dexamethasone is completely inhibited 
by actinomycin D. However, after preinduction with 
DBcAMP, simultaneous addition of actinomycin D 
and dexamethasone results in a dexamethasone-depen- 
dent increase in TAT synthesis. Apparently, DBcAMP 
causes a modulation of a regulatory site for TAT syn- 
thesis at a post-transcriptional evel which is sensitive 
for dexamethasone in this modulated form. 
Abbreviations: TAT, L-tyrosine:2-oxoglutarate aminotransfer- 
ase (EC 2.6.1 .5), DBcAMP, N6,0*‘-dibutyryl cyclic adenosine 
3’,5’-monophosphate; SDS, sodium dodecylsulphate 
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2. Materials and methods 
2.1. Cell culture 
Experiments were done with Reuber H35 cells 
grown as monolayers in basal Eagle’s medium enriched 
4-fold with amino acids and vitamins. The medium for 
growth contained 107r’ calf serum and 5% fetal calf 
serum; 20 h before the experiment the medium was 
replaced by serum-free medium. In the medium leucine 
was 0.8 mM. The specific activity of L-[3H]leucine 
during incorporation experiments was 13 Ci/mol. 
2.2. Ccl1 harvesting and ct~zyrne detemlination 
Monolayers were washed twice with icecold saline 
(0.15 M KCl, 1 mM EDTA). After freezing and thaw- 
ing, the cells were scraped off in 50 mM potassium 
phosphate buffer (pH 6.5) containing 0.1 mM pyri- 
doxal phosphate, 5 mM 2-oxoglutaric acid, 1 mM 
EDTA, 0.15 M KCl, 5 mM 2-mercaptoethanol and 0.1% 
Nonidet P40. Tyrosine aminotransferase activity was 
determined as in [ 111. Protein concentration was deter- 
mined as in [ 121. 
2.3, Dctemzination oj’ TA T SJW thesis ad degradation 
TAT synthesis was determined by incorporation of 
[“Hlleucine in the enzyme and the TAT degradation 
by disappearance of [3H]leucine from the enzyme. 
[“HI Leucine in TAT was determined by direct immu- 
noprecipitation in the cell lysates which were partially 
purified by incubation at 65°C for 5 min followed by 
removal of denatured proteins. The TAT-antibody 
precipitates were dissolved in 2% SDS and 3% dithio- 
threitol, heated for 30 min at 60°C and analyzed by 
SDS--polyacrylamide gel electrophoresis performed 
by a modification of the method in [ 131. Radioactiv- 
ity was eluted from the gel slices overnight at 37°C in 
a mixture of Lumasolve~l lzO~Lipolunia (1:0.2:9). 
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2.4. Specificity of the TAT antiserum 
The specificity of the antiserum has been demon- 
strated by SDS-polyacrylamide gel electrophoresis 
wherein a single peak of radioactivity of J4,. 50 OOO- 
55 000 is seen with first precipitates of labeled lysates 
and only scattered low radioactivity with the second. 
In addition, only a single precipitation arc is observed 
with two-dimensional crosselectrophoresis. 
2.5 . Materials 
DBcAMP and actinomycin D were purchased from 
Boehringer (Mannheim), dexamethasone was purchased 
from Sigma and L- [3H]leucine (126 Ci/mmol) was 
purchased from the Radiochemical Centre (Amersham). 
3. Results 
TAT activity in Reuber H35 cells is increased after 
treatment with dexamethasone or DBcAMP (fig.1). 
The induction of TAT by dexamethasone is completely 
inhibited by actinomycin D (fig.1 B). Actinomycin D 
does not block the early response to DBcAMP, al- 
though over time, inhibition of increasing intensity 
ensues (fig.1 A). The induction capacity in the presence 
of actinomycin Dis decreased as a consequence of the 
short half-life of TAT and TAT mRNA [14,15]. 
When the same experiment is carried out with cell 
cultures which are preincubated with DBcAMP for 
1 h, an induction of TAT activity by dexamethasone 
in the presence of actinomycin D occurs (fig.2A). The 
kinetics of this induction do not show the usual lagtime 
of -1.5 h before the increase in TAT activity after 
dexamethasone addition (fig.lB). The actinomycin 
D-insensitive induction was found either in the contin- 
uous presence of DBcAMP as well as after removal of 
DBcAMP. Apparently, the actinomycin D-insensitiv- 
ity is determined by the preinduction. The specificity 
of this pre-induction is further shown in the reversed 
situation,the influence of preinduction with dexa- 
methasone on DBcAMP-induced and/or dexameth- 
asoneinduced increase in TAT activity. Except for 
go- 
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Fig.1. The effect of actinomycin D on the induction of TAT activity by DBcAMP (A) and dexamethasone (B). Cells were grown 
as in section 2: DBcAMP (1 mM), dexamethasone (2 X 1 0m6 M) and/or actinomycin D (0.2 pg/ml) were added at zero time. (A) 
(A) + DBcAMP; (n) + DBcAMP + actinomycin D; (0) control cells; (0) control cells + actinomycin D. (B) (A) + dexamethasone; (A) 
+ dexamethasone + actinomycin D. 
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Fig.2. The effect of pre- or co-induction with DBcAMP on the induction of TAT activity (A) and TAT synthesis (B) by desamcth- 
asone in the presence of actinomycin D. Cells were grown as in section 2. DBcAMP was added I h before the start of the experi- 
ments. At i = 0 the cells were washed ,fresh serum-free medium was added and the following additions were made: (+) + dexamcth- 
asone; (A) + dexamethasone + DBcAMP + actinomycin D; (a) + DBcAMP + actinomycin D; (0) + dexamethasone + actinomycin D; 
(o) + actinomycin D. The final concentrations were: dexamethasone (2 X 1Om6 M); DBcAMP (1 mM); actinomycin D (0.2 #/ml). 
TATincrease due to pre-incubation,no dexamethasone 
effect was observed when added in the presence of 
actinomycin D (fig.3A) The DBcAMP induction of 
TATactivity is independent on pre- or co-induction 
with dexamethasone. 
The actinomycin D-independent increase in TAT 
activity after dexamethasone addition may be caused 
by an increased rate of TAT synthesis or an increased 
TAT stability. Fig.2B,3B show the rates of TAT syn- 
thesis under the various conditions. After pre-induc- 
tion with DBcAMP, dexamethasone is able to increase 
specifically TAT synthesis in the presence of actino- 
mycin D. 
To check if the addition of inducers and/or inhibi- 
tor affects the stability of TAT we determined the rate 
of degradation of the enzyme under the various exper- 
imental conditions. The results are presented in table 1. 
Conditions of induction show the same rates of TAT 
degradation as control cells. Actinomycin D decreases 
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the rate of degradation. However, the relatively small 
differences in rates of TAT degradation will have no 
significant effect on the measurement of the rate of 
TAT synthesis which is performed during 45 min 
labeling periods. Apparently, the modulation effect 
is due to changes in the rate of TAT synthesis. 
4. Discussion 
The mechanism by which steroid hormones regu- 
late the synthesis of TAT in rat liver and hepatoma 
cells has been extensively investigated. Evidence sup- 
porting hormonal control of specific gene transcrip- 
tion is formed by the complete inhibition of TATsyn- 
thesis by inhibitors of RNA synthesis [ 166191, by 
investigations on the hormone-receptor complex [20] 
and by determination of the levels of translatable TAT 
mRNA after hormone induction in cell-free protein 
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Fig.3. The effect of pre- or co-induction with dexamethasone on the induction of TAT activity (A) and TAT synthesis (B) by 
DBcAMP in the presence of actinomycin D. Cells were grown as in section 2. Dexamethasone was added 1 h before the start of 
the experiment. At r = 0 the cells were washed thoroughly and the following additions were made: (*) + dexamethasone; (A) 
+ dexamethasone + DBcAMP + actinomycin D; (A) + DBcAMP + actinomycin D; (0) + dexamethasone + actinomycin D; (0) 
+ actinomycin D. The final concentrations were: dexamethasone (2 X low6 M); DBcAMP (1 mM); actinomycin D (0.2 (pg/ml). 
Table I 
Degradation of TAT under different induction conditions 
- 
Addition at r = 0 TAT degraded 
from 2.5-6 h 
None 
Dexamethasone 
59% 
+ actinomycin D 
Actinomycin D 
DBcAMP + dexamethasone 
69%> 
43% 
+ actinomycin D 
DBcAMP + actinomycin D 
____ 
7 0% 
59% 
Cells were grown as in section 2. At t = 0, after 1 h preinduction 
with DBcAMP (1 mM), the cultures were washed, fresh serum- 
free medium was added and the cells were supplemented with 
either DBcAMP (1 mM), dexamethasone (2 X 10d6 M). acti- 
nomycin D (0.2 Mg/ml) or combinations of these compounds. 
At t = 1.5 h [3H]leucine was added. At t = 2.5 h the medium 
was removed, the cells were washed and the inducer(s) and/or 
inhibitor were added again in fresh serum-free medium. At 
t = 6 h the cells were harvested and the [3H]leucine incorpora- 
tion in TAT was determined. Data are expressed as radioactiv- 
ity present in TAT at i = 6 h as percentage of the radioactiv- 
ity present at t = 2.5 h 
synthesizing systems [21-231. The conclusion is that 
steroid hormones induce the TATsynthesis by increas- 
ing the rate of transcription of the TAT gene. 
Here, we describe an extragenomic effect of the 
synthetic corticosteroid dexamethasone on the TAT 
synthesis in a minimal deviation hepatoma cell line. 
This effect is dependent on pre- or co-induction with 
DBcAMP and is not inhibited by actinomycin D. 
Apparently, this is a new level on which DBcAMP can 
regulate the TAT synthesis. Until now the known 
levels of regulation of TAT activity by analogs of 
cAMPare transcription [9,10] and translational events 
occuring during elongation [8] and initiation [7]. 
Nothing is known about the mechanism of the 
DBcAMP-dependent induction of TAT synthesis by 
dexamethasone. Indications that it is a post-transcrip- 
tional event are formed by the actinomycin D-indepen- 
dency of the effect and the lack of lagtime in the 
increase of TAT activity after dexamethasone addition. 
In [24,25], addition of another hormone that in- 
duces TAT, cortisol, caused extragenomic effects in 
rat liver such as immediate phosphorylation of cyto- 
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plasmic proteins and activation of protein phospho- 
kinase and phosphatase activities. This indicates that 
hormonal effects do not have to be mediated by 
genomic events. 
Apparently, the regulation of the TAT activity is 
a very complex phenomenon. Probably the liver and 
hepatoma cells have the possibility to regulate the TAT 
activity via several specific mechanisms and it depends 
on the metabolic or culture conditions which mecha- 
nism is used. This variation in regulatory mechanisms 
offers the cell the possibility to regulate the TAT activ- 
ity fast and over a wide range without extreme varia- 
tions in the rates of transcription or translation. 
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